ERBB2 and adenocarcinoma: Preliminary data from a Phase II clinical trial shows promising results when using a combination of camrelizumab, trastuzumab, and chemotherapy as neoadjuvant therapy for Her-2 over-expressing G/GEJ adenocarcinoma.